X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
index medicus (10) 10
aged (9) 9
male (9) 9
female (8) 8
middle aged (8) 8
oncology (8) 8
chemotherapy (7) 7
colorectal cancer (7) 7
cancer (6) 6
colorectal neoplasms - drug therapy (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
colorectal neoplasms - genetics (5) 5
colorectal neoplasms - pathology (5) 5
metastasis (5) 5
oxaliplatin (5) 5
adult (4) 4
cancer patients (4) 4
cancer therapies (4) 4
disease-free survival (4) 4
fluorouracil (4) 4
fluorouracil - administration & dosage (4) 4
leucovorin (4) 4
leucovorin - administration & dosage (4) 4
proportional hazards models (4) 4
radiotherapy (4) 4
research (4) 4
trial (4) 4
aged, 80 and over (3) 3
analysis (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
camptothecin - administration & dosage (3) 3
camptothecin - analogs & derivatives (3) 3
clinical study (3) 3
kaplan-meier estimate (3) 3
metastases (3) 3
prognosis (3) 3
studies (3) 3
survival rate (3) 3
tumors (3) 3
1st-line treatment (2) 2
adenocarcinoma (2) 2
adenocarcinoma - mortality (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
braf (2) 2
care and treatment (2) 2
cetuximab (2) 2
chemoradiotherapy (2) 2
clinical trials (2) 2
colorectal neoplasms - mortality (2) 2
combined modality therapy (2) 2
digestive system diseases (2) 2
disease progression (2) 2
dna mutational analysis (2) 2
drug therapy (2) 2
epidermal growth factor (2) 2
fluorouracil - adverse effects (2) 2
follow-up studies (2) 2
genes, ras (2) 2
hematology, oncology and palliative medicine (2) 2
kras (2) 2
leucovorin - adverse effects (2) 2
life sciences (2) 2
liver (2) 2
liver cancer (2) 2
management (2) 2
medical treatment (2) 2
medicine, general & internal (2) 2
mutation (2) 2
oncology, experimental (2) 2
panitumumab (2) 2
patients (2) 2
phenylurea compounds - therapeutic use (2) 2
proteins (2) 2
proto-oncogene proteins b-raf - genetics (2) 2
pyridines - therapeutic use (2) 2
radiation therapy (2) 2
ras (2) 2
ras proteins - genetics (2) 2
research article (2) 2
retrospective studies (2) 2
safety (2) 2
surgery (2) 2
survival (2) 2
time factors (2) 2
treatment outcome (2) 2
vascular endothelial growth factor (2) 2
young adult (2) 2
[ sdv.bc ] life sciences [q-bio]/cellular biology (1) 1
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
[sdv.can]life sciences [q-bio]/cancer (1) 1
abridged index medicus (1) 1
acquired-resistance (1) 1
adenocarcinoma - blood (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - genetics (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 937 - 948
Summary Background Tumour mutational status is an important determinant of the response of metastatic colorectal cancer to targeted treatments. However, the... 
Hematology, Oncology and Palliative Medicine | KRAS MUTATIONS | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | RANDOMIZED PHASE-III | INHIBITS GROWTH | ACQUIRED-RESISTANCE | FLUOROURACIL | PLACEBO PLUS | TUMOR-GROWTH | Predictive Value of Tests | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Clinical Trials, Phase III as Topic | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Real-Time Polymerase Chain Reaction | Precision Medicine | Receptor, TIE-1 - blood | Phosphatidylinositol 3-Kinases - blood | Genetic Predisposition to Disease | Adenocarcinoma - blood | ras Proteins - blood | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Phenotype | Class I Phosphatidylinositol 3-Kinases | Biomarkers, Tumor - genetics | ras Proteins - genetics | Patient Selection | DNA, Neoplasm - blood | Female | Adenocarcinoma - genetics | Retrospective Studies | Pyridines - therapeutic use | Colorectal Neoplasms - mortality | Colorectal Neoplasms - blood | Kaplan-Meier Estimate | Proportional Hazards Models | Phenylurea Compounds - therapeutic use | Proto-Oncogene Proteins B-raf - blood | Proto-Oncogene Proteins - genetics | Treatment Outcome | Randomized Controlled Trials as Topic | Biomarkers, Tumor - blood | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Proto-Oncogene Proteins B-raf - genetics | Aged | DNA, Neoplasm - genetics | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins - blood | Adenocarcinoma - mortality | Medical colleges | Medical research | Cancer patients | Prognosis | Liver | DNA | Colorectal cancer | Genetic research | Medicine, Experimental | Metastasis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 184 - 190
Journal Article
by Pivot, Xavier and Romieu, Gilles and Debled, Marc and Pierga, Jean-Yves and Kerbrat, Pierre and Bachelot, Thomas and Lortholary, Alain and Espié, Marc and Fumoleau, Pierre and Serin, Daniel and Jacquin, Jean-Philippe and Jouannaud, Christelle and Rios, Maria and Abadie-Lacourtoisie, Sophie and Venat-Bouvet, Laurence and Cany, Laurent and Catala, Stéphanie and Khayat, David and Gambotti, Laetitia and Pauporté, Iris and Faure-Mercier, Celine and Paget-Bailly, Sophie and Henriques, Julie and Grouin, Jean Marie and Piprot, C and Cals, L and Chaigneau, L and Demarchi, F and N'Guyen, T and Stein, U and Villanueva, C and Bréau, JL and Chouahnia, AK and Saintigny, P and Boué, F and deSaint-Hilaire, P and Guimont, I and Grossat, N and Valenza, B and Lévy, E and Médioni, J and Delbaldo, C and Grenier, J and Pouessel, D and Lavau-Denès, S and Falandry, C and Fournel-Fédérico, C and Freyer, G and Tartas, S and Trillet-Lenoir, V and Bons, F and Auclerc, G and Chièze, S and Raban, N and Tournigand, C and Trager-Maury, S and Bousquet, G and Cuvier, C and Giacchetti, S and Hocini, A and LeMaignan, C and Misset, JL and Avenin, D and Beerblock, C and Gligorov, J and Rivera, P and Roché, H and Bougnoux, P and Hajjaji, N and Capitain, O and Delva, R and Maillart, P and Soulié, P and Bonnefoi, H and Durand, M and Madranges, N and Mauriac, L and Chollet, P and Dillies, AF and Durando, X and Ferrière, JP and Mouret-Reynier, C and Nabholtz, JM and Van Praagh, I and Cottu, P and Diéras, V and Durieux, A and Galotte, M and Girre, V and Henry, S and Iurisci, I and Jouve, M and Laurence, V and Mignot, L and Piperno-Neumann, S and Tresca, P and Coudert, B and Ferrant, E and Mayer, F and Vanneuville, AC and ... and PHARE Trial Investigators and PHARE trial investigators
The Lancet, ISSN 0140-6736, 06/2019, Volume 393, Issue 10191, pp. 2591 - 2598
Journal Article
Journal Article
Journal Article
BMC cancer, ISSN 1471-2407, 2012, Volume 12, Issue 1, pp. 438 - 438
Background: Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal... 
IRINOTECAN FOLFIRI | MANAGEMENT | EFFICACY | Panitumumab | Colorectal cancer | Tolerability | FLUOROURACIL | TUMORS | CHEMOTHERAPY | Quality of life | TRIAL | EGFR INHIBITORS | CETUXIMAB | ONCOLOGY | KRAS | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Skin Diseases - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Skin Diseases - pathology | Young Adult | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Skin - pathology | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Skin Diseases - chemically induced | Mutation - drug effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Aged | Colorectal Neoplasms - pathology | Genes, ras | Skin - drug effects | Usage | Patient outcomes | Analysis | Dosage and administration | Research | Drug therapy | Antimitotic agents | Cancer patients | Care and treatment | Chemotherapy | Epidermal growth factor | Monoclonal antibodies | Skin | Metastasis | Antineoplastic agents | Patient compliance | Cancer | Biotechnology industry
Journal Article
Journal Article
Journal Article
BMC Research Notes, ISSN 1756-0500, 11/2013, Volume 6, Issue 1, pp. 492 - 492
To evaluate the feasibility and efficacy of Stereotactic body radiation therapy (SBRT) for primary liver lesions and liver metastases treated with linear... 
metastases | HCC | Radiotherapy | Liver | SBRT | Humans | Liver Neoplasms - radiotherapy | Middle Aged | Radiosurgery | Aged, 80 and over | Female | Male | Aged | Liver cancer | CT imaging | Colorectal cancer | Radiation | Liver tumors | Metastasis | Medical imaging | Nuclear magnetic resonance--NMR | Medical treatment | Cancer
Journal Article